Winter CME Series Session 1: GU, GI and Thoracic Oncology
SESSION 1: JANUARY 24, 2024 – GU, GI and Thoracic Oncology
This first session of the University of Illinois Cancer Center three-part Winter CME Series aims to educate and update the knowledge of practitioners on advances in diagnosing and managing Genitourinary, Gastrointestinal and Thoracic Cancers. The target audience for this conference is medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals and other providers interested in the care of patients with cancer.
After participating in Session 1, learners will be better able to:
Evaluate the efficacy and safety of using PARP inhibitors in managing HRR-mutated metastatic prostate cancer, including potential side effects and monitoring parameters.
Review the latest guidelines and recommendations for peri-operative therapy in localized rectal cancer.
Identify the role and significance of biomarkers in early and advanced-stage non-small cell lung cancer.
Session 2 of the series (women’s cancers) is scheduled for January 31 and Session 3 (hematologic malignancies) is scheduled for February 7. The conference will be live in person and offered online via live broadcast. The conference also will be recorded and posted online for on-demand access 60-90 days later.
AGENDA
Wednesday, January 24, 2024
1 – 2:30 p.m. – Registration, Exhibits, Ancillary Events
2:30 – 2:35 p.m. – Introduction
2:35 – 3:20 p.m. – Shifting Paradigms: How PARP Inhibitors are Reshaping the Treatment of HRR-Mutated Metastatic Prostate Cancer
3:20 – 4:05 p.m. – The Evolving Landscape of Peri-operative Therapy for Localized Rectal Cancer: What Clinicians Need to Know
4:05 – 4:20 p.m. – Break, Exhibits
4:20 – 5:05 p.m. – Navigating Neoadjuvant Options: Current Updates in the Perioperative Treatment for Early-Stage Lung Cancer
5:05 – 5:50 p.m. – Precision Oncology: Leveraging Biomarkers for First-Line Treatment in NSCLC
5:50 – 7 p.m. – Exhibits, Ancillary Events
1 – 2:30 p.m. – Registration, Exhibits, Ancillary Events
2:30 – 2:35 p.m. – Introduction
2:35 – 3:20 p.m. – Shifting Paradigms: How PARP Inhibitors are Reshaping the Treatment of HRR-Mutated Metastatic Prostate Cancer
3:20 – 4:05 p.m. – The Evolving Landscape of Peri-operative Therapy for Localized Rectal Cancer: What Clinicians Need to Know
4:05 – 4:20 p.m. – Break, Exhibits
4:20 – 5:05 p.m. – Navigating Neoadjuvant Options: Current Updates in the Perioperative Treatment for Early-Stage Lung Cancer
5:05 – 5:50 p.m. – Precision Oncology: Leveraging Biomarkers for First-Line Treatment in NSCLC
5:50 – 7 p.m. – Exhibits, Ancillary Events
VK Gadi, MD, PhD
Professor and Director, Medical Oncology
Deputy Director
University of Illinois Cancer Center
Chicago, IL
Professor and Director, Medical Oncology
Deputy Director
University of Illinois Cancer Center
Chicago, IL
CO-CHAIR
Ryan Nguyen, DO
Assistant Professor of Clinical Medicine
Director, Precision Oncology Tumor Board
University of Illinois Cancer Center
Chicago, IL
Assistant Professor of Clinical Medicine
Director, Precision Oncology Tumor Board
University of Illinois Cancer Center
Chicago, IL
FACULTY
Natalie Reizine, MD
University of Illinois Cancer Center
Chicago, IL
University of Illinois Cancer Center
Chicago, IL
Shikha Jain, MD, FACP
University of Illinois Cancer Center
Chicago, IL
University of Illinois Cancer Center
Chicago, IL
Frank Weinberg, MD, PhD
University of Illinois Cancer Center
Chicago, IL
University of Illinois Cancer Center
Chicago, IL